** Shares of soft-tissue regeneration products maker Aroa Biosurgery ARX.AX rise as much as 12.5% to A$0.72, their highest level since January 27

** The New Zealand-based co expects its FY26 results to fall at the upper end of the revenue forecast range of NZ$92 million to NZ$100 million ($55.36 million to $60.17 million) and normalised EBITDA of NZ$5 million to NZ$8 million

** About 148,390 shares change hands, 1.5x the 30-day average

** YTD, stock down 2.7% this year, including the day's move

($1 = 1.6620 New Zealand dollars)

(Reporting by Sherin Sunny in Bengaluru)

((Sherin.Sunny@thomsonreuters.com))